As of Apr 20
| +0.14 / +0.08%|
The 14 analysts offering 12-month price forecasts for United Therapeutics Corp have a median target of 152.00, with a high estimate of 198.00 and a low estimate of 92.00. The median estimate represents a -17.98% decrease from the last price of 185.33.
The current consensus among 16 polled investment analysts is to Buy stock in United Therapeutics Corp. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.